Table of contents
- Trial overview
- Study design and phase
- Who can participate
- What is being measured
- Comparison treatments in the study
- Patient-friendly explanation of key terms
Trial overview
This clinical trial is studying type 2 diabetes in adults and is listed as Authorised.[1]
The study is an interventional trial, which means researchers are giving treatments and then measuring the results.[1]
Although the trial title focuses on once-weekly insulin icodec, the treatment list includes INSULIN DETEMIR as one of the daily basal insulin options used for comparison.[1]
Study design and phase
This is a Phase 3 study, which is a later-stage trial usually done in a larger group of people to compare how well treatments work.[1]
The planned enrollment is 510 participants.[1]
The trial is designed to compare once-weekly insulin icodec with once-daily basal insulin analogues used at the investigator’s discretion in real-world clinical practice.[1]
Who can participate
The study is for adults with type 2 diabetes.[1]
The brief summary says participants are already using non-insulin glucose-lowering medications and need treatment intensification, which means their current treatment is not enough and a stronger plan is being tested.[1]
No other detailed inclusion or exclusion rules are given in the source data, so only this target population can be confirmed here.[1]
What is being measured
The main endpoint, or main result being measured, is the change in HbA1c from baseline week 0 to week 52.[1]
HbA1c is a blood test that shows average blood sugar over time, so this outcome helps researchers see whether treatment improves long-term glucose control.[1]
The study compares the difference in HbA1c change between once-weekly insulin icodec and once-daily basal insulin analogues, and it uses a non-inferiority limit of 0.3%.[1]
Comparison treatments in the study
The intervention list includes several basal insulin products, and INSULIN DETEMIR appears as Levemir FlexPen and Levemir Penfill in the study materials.[1]
Other comparison treatments listed in the trial include Lantus, Toujeo, Tresiba, and Awiqli, all given by subcutaneous injection, which means injection under the skin.[1]
The source data does not describe the results of these comparisons yet, so the article can only report the study plan and endpoints, not final findings.[1]
Patient-friendly explanation of key terms
Basal insulin means insulin used to help keep blood sugar steady through the day and night.[1]
Treatment intensification means adding or changing treatment when current medicines are not enough.[1]
Real-world clinical practice means the treatment is being studied in everyday care, not only in a highly controlled research setting.[1]
Non-inferiority means the study is checking whether one treatment is not worse than another by more than a small allowed amount.[1]
